1887

Journal of General Virology header logo

Volume 89, Issue 1

-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef Free

Abstract

Myristoylation of the human immunodeficiency virus type 1 (HIV-1) proteins Gag and Nef by -myristoyltransferase (NMT) is a key process in retroviral replication and virulence, yet remains incompletely characterized. Therefore, the roles of the two isozymes, NMT1 and NMT2, in myristoylating Gag and Nef were examined using biochemical and molecular approaches. Fluorescently labelled peptides corresponding to the N terminus of HIV-1 Gag or Nef were myristoylated by recombinant human NMT1 and NMT2. Kinetic analyses indicated that NMT1 and NMT2 had 30- and 130-fold lower values for Nef than Gag, respectively. Values for indicated that, once Gag or Nef binds to the enzyme, myristoylation by NMT1 and NMT2 proceeds at comparable rates. Furthermore, the catalytic efficiencies for the processing of Gag by NMT1 and NMT2 were equivalent. In contrast, NMT2 had approximately 5-fold higher catalytic efficiency for the myristoylation of Nef than NMT1. Competition experiments confirmed that the Nef peptide acts as a competitive inhibitor for the myristoylation of Gag. Experiments using full-length recombinant Nef protein also indicated a lower for Nef myristoylation by NMT2 than NMT1. Small interfering RNAs were used to selectively deplete NMT1 and/or NMT2 from HEK293T cells expressing a recombinant Nef–sgGFP fusion protein. Depletion of NMT1 had minimal effect on the intracellular distribution of Nef–sgGFP, whereas depletion of NMT2 altered distribution to a diffuse, widespread pattern, mimicking that of a myristoylation-deficient mutant of Nef–sgGFP. Together, these findings indicate that Nef is preferentially myristoylated by NMT2, suggesting that selective inhibition of NMT2 may provide a novel means of blocking HIV virulence.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83412-0
2008-01-01
2024-04-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/1/288.html?itemId=/content/journal/jgv/10.1099/vir.0.83412-0&mimeType=html&fmt=ahah

References

  1. Bentham M., Mazaleyrat S., Harris M. 2006; Role of myristoylation and N-terminal basic residues in membrane association of the human immunodeficiency virus type 1 Nef protein. J Gen Virol 87:563–571 [CrossRef]
     [Google Scholar]
  2. Bohlen P., Stein S., Dairman W., Udenfriend S. 1973; Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys 155:213–220 [CrossRef]
     [Google Scholar]
  3. Bouamr F., Scarlata S., Carter C. 2003; Role of myristylation in HIV-1 Gag assembly. Biochemistry 42:6408–6417 [CrossRef]
     [Google Scholar]
  4. Bryant M., Ratner L. 1990; Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87:523–527 [CrossRef]
     [Google Scholar]
  5. Bryant M. L., Heuckeroth R. O., Kimata J. T., Ratner L., Gordon J. I. 1989; Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. Proc Natl Acad Sci U S A 86:8655–8659 [CrossRef]
     [Google Scholar]
  6. Bryant M. L., Ratner L., Duronio R. J., Kishore N. S., Devadas B., Adams S. P., Gordon J. I. 1991; Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 Gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line. Proc Natl Acad Sci U S A 88:2055–2059 [CrossRef]
     [Google Scholar]
  7. Coffin J. M., Hughes S. H., Varmus H. E. 2002 Retroviruses electronic version Woodbury, NY: Cold Spring Harbor Press;
     [Google Scholar]
  8. Devadas B., Lu T., Katoh A., Kishore N. S., Wade A. C., Mehta P. P., Rudnick D. A., Bryant M. L., Adams S. P. other authors 1992; Substrate specificity of Saccharomyces cerevisiae myristoyl-CoA: protein N -myristoyltransferase. Analysis of fatty acid analogs containing carbonyl groups, nitrogen heteroatoms, and nitrogen heterocycles in an in vitro enzyme assay and subsequent identification of inhibitors of human immunodeficiency virus I replication. J Biol Chem 267:7224–7239
     [Google Scholar]
  9. Ducker C. E., Upson J. J., French K. J., Smith C. D. 2005; Two N -myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol Cancer Res 3:463–476 [CrossRef]
     [Google Scholar]
  10. Fackler O. T., Moris A., Tibroni N., Giese S. I., Glass B., Schwartz O., Krausslich H. G. 2006; Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 351:322–339 [CrossRef]
     [Google Scholar]
  11. French K. J., Zhuang Y., Schrecengost R. S., Copper J. E., Xia Z., Smith C. D. 2004; Cyclohexyl-octahydro-pyrrolo[1,2- α ]pyrazine-based inhibitors of human N -myristoyltransferase-1. J Pharmacol Exp Ther 309:340–347 [CrossRef]
     [Google Scholar]
  12. Garcia J. V., Miller A. D. 1992; Downregulation of cell surface CD4 by Nef. Res Virol 143:52–55 [CrossRef]
     [Google Scholar]
  13. Giang D. K., Cravatt B. F. 1998; A second mammalian N -myristoyltransferase. J Biol Chem 273:6595–6598 [CrossRef]
     [Google Scholar]
  14. Gottlinger H. G., Sodroski J. G., Haseltine W. A. 1989; Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86:5781–5785 [CrossRef]
     [Google Scholar]
  15. Greenberg M. E., Bronson S., Lock M., Neumann M., Pavlakis G. N., Skowronski J. 1997; Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J 16:6964–6976 [CrossRef]
     [Google Scholar]
  16. Greenway A. L., Holloway G., McPhee D. A., Ellis P., Cornall A., Lidman M. 2003; HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication. J Biosci 28:323–335 [CrossRef]
     [Google Scholar]
  17. Guy B., Kieny M. P., Riviere Y., Le Peuch C., Dott K., Girard M., Montagnier L., Lecocq J. P. 1987; HIV F/3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 330:266–269 [CrossRef]
     [Google Scholar]
  18. Harris M. 1995; The role of myristoylation in the interactions between human immunodeficiency virus type I Nef and cellular proteins. Biochem Soc Trans 23:557–561
     [Google Scholar]
  19. Harris M. 1999; HIV: a new role for Nef in the spread of HIV. Curr Biol 9:R459–R461 [CrossRef]
     [Google Scholar]
  20. Harris M. P., Neil J. C. 1994; Myristoylation-dependent binding of HIV-1 Nef to CD4. J Mol Biol 241:136–142 [CrossRef]
     [Google Scholar]
  21. Heuckeroth R. O., Gordon J. I. 1989; Altered membrane association of p60v-src and a murine 63-kDa N -myristoyl protein after incorporation of an oxygen-substituted analog of myristic acid. Proc Natl Acad Sci U S A 86:5262–5266 [CrossRef]
     [Google Scholar]
  22. Hill B. T., Skowronski J. 2005; Human N -myristoyltransferases form stable complexes with lentiviral Nef and other viral and cellular substrate proteins. J Virol 79:1133–1141 [CrossRef]
     [Google Scholar]
  23. Jacobs E., Gheysen D., Thines D., Francotte M., de Wilde M. 1989; The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane. Gene 79:71–81 [CrossRef]
     [Google Scholar]
  24. Kaminchik J., Margalit R., Yaish S., Drummer H., Amit B., Sarver N., Gorecki M., Panet A. 1994; Cellular distribution of HIV type 1 Nef protein: identification of domains in Nef required for association with membrane and detergent-insoluble cellular matrix. AIDS Res Hum Retroviruses 10:1003–1010 [CrossRef]
     [Google Scholar]
  25. Lindwasser O. W., Resh M. D. 2002; Myristoylation as a target for inhibiting HIV assembly: unsaturated fatty acids block viral budding. Proc Natl Acad Sci U S A 99:13037–13042 [CrossRef]
     [Google Scholar]
  26. Miller M. D., Warmerdam M. T., Gaston I., Greene W. C., Feinberg M. B. 1994; The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179:101–113 [CrossRef]
     [Google Scholar]
  27. Olszewski A., Sato K., Aron Z. D., Cohen F., Harris A., McDougall B. R., Robinson W. E. Jr, Overman L. E., Weiss G. A. 2004; Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck . Proc Natl Acad Sci U S A 101:14079–14084 [CrossRef]
     [Google Scholar]
  28. Pal R., Reitz M. S. Jr, Tschachler E., Gallo R. C., Sarngadharan M. G., Veronese F. D. 1990; Myristoylation of Gag proteins of HIV-1 plays an important role in virus assembly. AIDS Res Hum Retroviruses 6:721–730 [CrossRef]
     [Google Scholar]
  29. Peng B., Robert-Guroff M. 2001; Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol Lett 78:195–200 [CrossRef]
     [Google Scholar]
  30. Rocque W. J., McWherter C. A., Wood D. C., Gordon J. I. 1993; A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA : protein N -myristoyltransferase. J Biol Chem 268:9964–9971
     [Google Scholar]
  31. Scarlata S., Carter C. 2003; Role of HIV-1 Gag domains in viral assembly. Biochim Biophys Acta 1614:62–72 [CrossRef]
     [Google Scholar]
  32. Shaheduzzaman S., Krishnan V., Petrovic A., Bittner M., Meltzer P., Trent J., Venkatesan S., Zeichner S. 2002; Effects of HIV-1 Nef on cellular gene expression profiles. J Biomed Sci 9:82–96 [CrossRef]
     [Google Scholar]
  33. Takamune N., Misumi S., Furuishi K., Shoji S. 1999; Blockage of HIV-1 production through inhibition of proviral DNA synthesis by N , O -didecanoyl serinal dimethylacetal. IUBMB Life 48:311–315 [CrossRef]
     [Google Scholar]
  34. Takamune N., Tanaka T., Takeuchi H., Misumi S., Shoji S. 2001; Down-regulation of N -myristoyl transferase expression in human T-cell line CEM by human immunodeficiency virus type-1 infection. FEBS Lett 506:81–84 [CrossRef]
     [Google Scholar]
  35. Takamune N., Hamada H., Misumi S., Shoji S. 2002; Novel strategy for anti-HIV-1 action: selective cytotoxic effect of N- myristoyltransferase inhibitor on HIV-1-infected cells. FEBS Lett 527:138–142 [CrossRef]
     [Google Scholar]
  36. Tashiro A., Shoji S., Kubota Y. 1989; Antimyristoylation of the gag proteins in the human immunodeficiency virus-infected cells with N -myristoyl glycinal diethylacetal resulted in inhibition of virus production. Biochem Biophys Res Commun 165:1145–1154 [CrossRef]
     [Google Scholar]
  37. Varner A. S., De Vos M. L., Creaser S. P., Peterson B. R., Smith C. D. 2002; A fluorescence-based high performance liquid chromatographic method for the characterization of palmitoyl acyl transferase activity. Anal Biochem 308:160–167 [CrossRef]
     [Google Scholar]
  38. Varner A. S., Ducker C. E., Xia Z., Zhuang Y., De Vos M. L., Smith C. D. 2003; Characterization of human palmitoyl-acyl transferase activity using peptides that mimic distinct palmitoylation motifs. Biochem J 373:91–99 [CrossRef]
     [Google Scholar]
  39. Veronese F. D., Copeland T. D., Oroszlan S., Gallo R. C., Sarngadharan M. G. 1988; Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol 62:795–801
     [Google Scholar]
  40. Welker R., Harris M., Cardel B., Krausslich H. G. 1998; Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J Virol 72:8833–8840
     [Google Scholar]
  41. Yang S. H., Shrivastav A., Kosinski C., Sharma R. K., Chen M. H., Berthiaume L. G., Peters L. L., Chuang P. T., Young S. G., Bergo M. O. 2005; N -myristoyltransferase 1 is essential in early mouse development. J Biol Chem 280:18990–18995 [CrossRef]
     [Google Scholar]
  42. Yu G., Felsted R. L. 1992; Effect of myristoylation on p27nef subcellular distribution and suppression of HIV-LTR transcription. Virology 187:46–55 [CrossRef]
     [Google Scholar]
  43. Zhou W., Parent L. J., Wills J. W., Resh M. D. 1994; Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 68:2556–2569
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83412-0
Loading
N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef
J. Gen. Virol. 89, 288 (2008); https://doi.org/10.1099/vir.0.83412-0
/content/journal/jgv/10.1099/vir.0.83412-0
/content/journal/jgv/10.1099/vir.0.83412-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error